Polaris Partners

1366 Technologies Inc. is a manufacturer of silicon wafers primarily used in solar cell modules. Founded in 2007 and based in Bedford, Massachusetts, the company specializes in producing 3D direct wafers and traditional silicon solar wafers. Its innovative technology allows for the direct creation of silicon wafers from molten silicon, resulting in lower production costs, reduced energy requirements, and improved uniformity. This approach enables businesses to develop solar cells that offer a better price-to-performance ratio. 1366 Technologies has established strategic partnerships with Hanwha Q CELLS and operates additional locations in Shanghai, China, and Mumbai, India.

Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, including Alzheimer's and frontotemporal dementia. The company's lead product, AL001, is a humanized recombinant monoclonal antibody currently in phase II clinical trials for frontotemporal dementia. Additionally, AL101 is in phase I clinical trials for various neurodegenerative diseases, while AL002 and AL003 are undergoing phase 1b trials specifically for Alzheimer's disease. Alector is leveraging advancements in antibody technology, neuroimmunology, and human genetics to create innovative therapeutics. The company maintains a collaboration with Adimab, LLC, which aids in the discovery and optimization of antibody therapeutics. Alector has a pipeline of ten programs in the research and development stage and aims to advance several candidates through pre-clinical development within the next two years. Founded in 2013, Alector is headquartered in South San Francisco, California.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.

Avitide, Inc. specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. The company focuses on developing customized affinity separation technology that streamlines bioprocess development, minimizes program risks, enhances predictability in commercial scalability, and lowers manufacturing costs. Its innovative affinity purification solutions cater to the production of various life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Incorporated in 2012 and based in Lebanon, New Hampshire, Avitide is recognized for its rapid development service timeline, positioning itself as a key player in the biopharmaceutical sector.

Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.

T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.

Neuronetics is a medical technology company based in Malvern, Pennsylvania, established in 2003. It specializes in developing non-invasive therapies for psychiatric and neurological disorders, particularly Major Depressive Disorder (MDD). The company's flagship product, the NeuroStar Advanced Therapy System, utilizes transcranial magnetic stimulation (TMS) to deliver MRI-strength magnetic pulses that induce electrical currents in targeted areas of the brain associated with mood regulation. This innovative treatment is the first of its kind to receive FDA clearance for patients who have not found relief from traditional antidepressant therapies. Neuronetics aims to improve the quality of life for individuals suffering from mental health conditions through its advanced, non-systemic treatment options.

MarkMonitor is a leading provider of enterprise brand protection services based in San Francisco, California. The company specializes in safeguarding brands, reputation, and revenue from online threats such as fraud, brand abuse, and unauthorized distribution channels. MarkMonitor delivers comprehensive solutions that include domain management and monitoring to prevent online brand abuse and combat the illegal distribution of pirated digital content. By utilizing its exclusive data access and patented real-time prevention and response capabilities, MarkMonitor effectively addresses the evolving online risks faced by businesses, helping to protect them from phishing, malware attacks, and other digital threats.

Impinj, Inc. operates a platform that enables wireless connectivity to everyday items, delivering vital information regarding identity, location, and authenticity to various business and consumer applications. The company specializes in RAIN RFID solutions, which include endpoint integrated circuits (ICs) that attach to items, as well as connectivity products such as readers, gateways, and reader ICs. These components work together to wirelessly identify, locate, authenticate, and engage items, facilitating bidirectional communication and power supply. Impinj's software offerings, notably ItemSense, enhance enterprise management through deployment tools and APIs for developers. The company serves a diverse range of sectors, including retail, healthcare, automotive, and logistics, through partnerships with distributors and system integrators across the Americas, Asia Pacific, Europe, the Middle East, and Africa. Founded in 2000 and headquartered in Seattle, Washington, Impinj is recognized for its comprehensive and widely adopted RAIN RFID product portfolio.

Heavy operates as a digital media platform that delivers timely news and information through its primary website, Heavy.com, and its Spanish-language counterpart, AhoraMismo.com. Originally launched in 1999 as a video-focused site for young men, it transitioned to a news platform in 2012 and currently attracts nearly 25 million monthly readers. The company's content is shaped by data on popular stories and trends, with an editorial team that includes experienced journalists and independent writers dedicated to quality and efficiency. Heavy is known for its rapid reporting, often ahead of mainstream outlets, and utilizes user-friendly formats, such as "5 Fast Facts," to present key information on trending topics. AhoraMismo serves the U.S. Hispanic community by providing news and resources on a variety of subjects, including entertainment, health, and politics, empowering readers to stay informed and enhance their daily lives.

Microbia an industrial biotechnology company, engages in the development, production, and commercialization of specialty ingredients and biomaterials utilizing fermentation technology. Its products include carotenoids, specialty ingredients, biopolymers, and other biomaterials. The company has a strategic alliance with Tate & Lyle Investments, Ltd. to develop and commercialize fermentation-derived renewable ingredients.

eRealty.com is an online residential real estate brokerage firm that assists buyers and sellers of homes. The company was founded in 1998 and is based in Houston, Texas.

"Incentive Systems is the industry pioneer and leader in the Enterprise Incentive Management marketplace, which is predicted by AMR to grow rapidly, reaching an annual market size of $2 billion in software revenue alone in 2005, and is also the first software company in which Thomas Weisel Capital Partners, LP made a private equity investment," said Alan Menkes, partner, co-director of private equity for Thomas Weisel Partners LLC. "Since their initial investment, Incentive Systems has continued to deliver industry-leading technology and services to the marketplace, and has seen tremendous growth in demand for its solutions, among both public and private organizations, across several industries. The company is on track to reach its goal of profitability in the near-term, and they were delighted by the oppornity to lead this round and further strengthen their partnership with Incentive Systems."